Hereditary transthyretin amyloidosis (hATTR), also known as familial amyloid polyneuropathy (FAP), is a rare and inherited disorder characterized by the abnormal accumulation of amyloid fibrils in various organs and tissues of the body. Amyloid fibrils are misfolded proteins that clump together and can lead to organ dysfunction over time.
Access Full Report @ https://www.databridgemarketresearch.com/reports/middle-east-and-africa-hereditary-transthyretin-amyloidosis-market
Transthyretin (TTR) is a protein primarily produced by the liver, and its normal function is to transport thyroxine (a thyroid hormone) and retinol (a form of vitamin A) in the blood. In hATTR, a genetic mutation causes the transthyretin protein to become unstable and more likely to misfold, leading to the formation of amyloid deposits.
The prevalence of hereditary transthyretin amyloidosis (hATTR) is on the rise due to various factors. Firstly, improved Genetic testing methods have made it easier and more affordable to identify individuals at risk for hATTR, leading to earlier diagnosis and a better understanding of the disease's prevalence. In addition, increased awareness of hATTR among medical professionals and the general public has resulted in more cases being recognized and diagnosed.
Thus, the rising prevalence of hereditary transthyretin amyloidosis is expected to act as a driver in the Middle East and Africa hereditary transthyretin amyloidosis market growth.
Data Bridge Market Research analyzes that the Middle East and Africa Hereditary Transthyretin Amyloidosis Market is expected to grow with a CAGR of 3.1% in the forecast period of 2023 to 2030 and is expected to reach USD 65,985.45 thousand by 2030. The diagnosis segment is projected to propel the market growth owing to a rise in approval of various diagnostic procedures for hereditary transthyretin amyloidosis.
Key Findings of the Study
Government Initiatives For Hereditary Transthyretin Amyloidosis Treatment
Increasing recognition by governmental bodies for the importance of addressing hereditary transthyretin amyloidosis (hATTR) and providing better support for affected individuals. These governmental initiatives are driven by the understanding that hATTR is a rare and severe genetic disease with a significant impact on patients' lives. The initiatives aim to improve awareness, research, patient care, and access to effective treatments for hATTR.
One crucial aspect of governmental initiatives is research funding. Governments have allocated funds to support scientific research on hATTR, both at the basic science level and for clinical studies. These funds encourage scientists and medical researchers to explore the disease's underlying mechanisms, identify potential therapeutic targets, and develop novel treatment approaches. By providing financial support to research projects, governments contribute to advancing knowledge about hATTR and potentially finding better ways to manage and treat the disease.
Government initiatives will improve healthcare infrastructure creating opportunities for targeted therapies and personalized treatments to address the diverse genetic mutations and disease characteristics of hATTR.
Thus, government initiatives for hereditary transthyretin amyloidosis is expected to act as an opportunity for the Middle East and Africa hereditary transthyretin amyloidosis market growth.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Thousand, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Diagnosis and Treatment (Diagnosis and Treatment), Gene Variation (V122L, T60A, V30M, and Others), Gender (Male and Female), Indication (Cardiomyopathy) (ATTR-CM), Polyneuropathy (ATTR-PN), and Mixed Indications), End User (Hospitals and Clinics, Diagnostic Laboratories, Radiology Centers, Academic and Research Institutes, Ambulatory Surgical Centers, and Homecare) Distribution Channel (Direct Tender, Third Party Distributors, Hospital Pharmacy, Retail Pharmacy, and Others)
|
|
Countries Covered
|
South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of Middle East and Africa
|
|
Market Players Covered
|
Pfizer Inc. (U.S.), Koninklijke Philips N.V. (Netherlands), Siemens Healthcare GmbH (Germany), CANON MEDICAL SYSTEMS CORPORATION (Japan), MinFound Medical Systems Co. (China), Alnylam Pharmaceuticals, Inc. (U.S.), NIHON KOHDEN CORPORATION. (Japan), GE HealthCare. (A Subsidary of General Electric) (U.S.), FONAR Corp. (U.S.), Neusoft Corporation (China), Shimadzu Corporation (Japan), SCHILLER (Switzerland), Novo Nordisk A/S (U.S.), and AstraZeneca (U.K.) among others.
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis
Middle East and Africa hereditary transthyretin amyloidosis market is segmented into six notable segments, diagnosis and treatment, gene variation, gender, indication, end user, and distribution channel.
- On the basis of diagnosis and treatment, the market is segmented into diagnosis and treatment.
In 2023, the diagnosis segment is expected to dominate the Middle East and Africa hereditary transthyretin amyloidosis market
In 2023, the diagnosis segment is expected to dominate the market with 59.94% market share due to the rise in approval of various diagnostic procedures for hereditary transthyretin amyloidosis.
- On the basis of gene variation, the market is segmented into V122L, T60A, V30M, and others.
In 2023, the V122L segment is expected to dominate the Middle East and Africa hereditary transthyretin amyloidosis market
In 2023, the V122L segment is expected to dominate the market with 54.86% market share as it is one of the most common mutations associated with hATTR and has a relatively high prevalence in certain populations.
- On the basis of gender, the market is segmented into male and female. In 2023, the male segment is expected to dominate the market with 56.71% market share.
- On the basis of indications, the market is segmented into cardiomyopathy (ATTR-CM), polyneuropathy (ATTR-PN), and mixed indications. In 2023, the cardiomyopathy (ATTR-CM) segment is expected to dominate the market with 46.10% market share.
- On the basis of end user, the market is segmented into hospitals and clinics, diagnostic laboratories, radiology centers, academic and research institutes, Ambulatory Surgical Centers, and homecare. In 2023, the hospitals and clinics segments are expected to dominate the market with 34.52% market share.
- On the basis of distribution channel, the market is segmented into direct tender, third party distributors, hospital pharmacy, retail pharmacy, and others. In 2023, the direct tender segment is expected to dominate the market with 41.94% market share.
Major Players
Data Bridge Market Research recognizes the following companies as the market players in the Middle East and Africa hereditary transthyretin amyloidosis market Pfizer Inc. (U.S.), Koninklijke Philips N.V. (Netherlands), Siemens Healthcare GmbH (Germany), CANON MEDICAL SYSTEMS CORPORATION (Japan), GE HealthCare. (A Subsidary of General Electric) (U.S.), among others.
Market Development
- In April 2023, Canon Medical Systems Corporation announced that it had begun clinical research by employing a next-generation X-ray CT system with photon counting computed tomography with the National Cancer Center Japan (NCC) . This will help the organization in developing its products category.
- In December 2022, a new technology AIR Recon DL was recently recognized in the “Best of What's New” awards by Popular Science magazine. It is a new technique developed by GE Healthcare for delivering high-quality images in a short amount of time. AIR Recon DL uses deep-learning technology to simultaneously improve MRI image quality and enable reduced scan time, improving the patient experience.
- In March 2022, Koninklijke Philips N.V. announced that it had showcased its state-of-the-art AI-driven enterprise imaging portfolio, which include digital imaging platforms, advanced informatics, and a suite of services at the 74th Annual Conference of the Indian Radiological and Imaging Association (IRIA) 2022. This helped the organization in developing the brand image globally.
- In December 2021, Pfizer Inc. announced publication of a post-hoc, interim analysis that showed treatment with Vyndaqel/Vyndamax reduced the risk of all-cause mortality at five years, providing a clinically significant survival benefit for patients with transthyretin amyloid cardiomyopathy (ATTR-CM). The analysis from the Phase 3 Transthyretin Amyloid Cardiomyopathy Clinical Trial (ATTR-ACT) and its long-term extension (LTE) study was published in Circulation. This helped the organisation in developing its brand image.
- In August 2020, Siemens Healthcare GmbH announced it had that entered into an agreement with Varian Medical Systems, Inc. This helped the organisation in developing advanced solutions and increased its product category.
Regional Analysis
Geographically, the countries covered in the Middle East and Africa hereditary transthyretin amyloidosis market report are South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of Middle East and Africa.
As per Data Bridge Market Research analysis:
South Africa is expected to dominate and be the fastest-growing country in the Middle East and Africa hereditary transthyretin amyloidosis market
South Africa is expected to dominate the market and be the fastest-growing due to the increase in disease awareness and education among both healthcare professionals and the public have likely contributed to the identification and management of conditions, such as hereditary transthyretin amyloidosis.
For more detailed information about the Middle East and Africa hereditary transthyretin amyloidosis market report, click here – https://www.databridgemarketresearch.com/reports/middle-east-and-africa-hereditary-transthyretin-amyloidosis-market
